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Fig.　1　Clinical photographs (a, b) and histopathological study (c). (a, chest and abdomen; b, back) At fi rst visit. 
(c) The histopathological fi ndings were consistent with maculopapular eruption (hematoxylin and eosin staining; 
original magnifi cation ×200).
a b c
Dear Editor
Maculopapular-Type Drug Eruption
Caused by Sitagliptin Phosphate
Hydrate: A Case Report and
Mini-Review of the Published Work
Sitagliptin phosphate hydrate (Januvia; MSD, Tokyo,
Japan) is an oral hypoglycemic drug, classified as a
dipeptidyl peptidase IV (DPP IV) inhibitor for pa-
tients with type 2 diabetes.1 It is a relatively new drug
that was approved in the United States of America,
the European Union, and Japan in 2006, 2007, and
2009, respectively. It is currently approved in 120
countries and regions worldwide (as of March 2013).
Here, we report the case of a 63-year-old woman diag-
nosed with maculopapular eruption caused by sita-
gliptin phosphate hydrate, and review this case to-
gether with 4 cases reported in the English language
literature.
A 63-year-old Japanese woman was referred to our
department for diagnosis of pruritic eruptions on the
trunk and extremities. She stated that she had taken
glimepiride (Amaryl; Sanofi, Tokyo, Japan), voglibose
(Basen; Takeda Chemical Industries, Osaka, Japan),
and metformin hydrochloride (Metgluco; Dainippon
Sumitomo Pharma, Osaka, Japan) for 10 years and si-
tagliptin phosphate hydrate for 4 months for type 2
diabetes mellitus, and pravastatin sodium (Mevalotin;
Daiichi Sankyo, Tokyo, Japan) for 1 year for hyperli-
pemia. Three months before her first visit to our de-
partment, she noticed the eruptions. At her former
hospital, she was started on prednisolone 15 mgday
for 4 days followed by 10 mgday for 7 days. In an in-
itial physical examination at our department, erythe-
matous and maculopapular lesions were present on
the trunk and extremities (Fig. 1a, b), but there were
no mucosal lesions associated with Stevens-Johnson
syndrome. Based on the medical history, drug erup-
tion caused by sitagliptin phosphate hydrate was sus-
pected. Administration of sitagliptin phosphate hy-
drate was discontinued. A skin biopsy obtained from
an erythematous papule on the back showed liquefac-
tion degeneration at the dermal-epidermal interface,
slight edema in the upper dermis, and mild lympho-
cytic infiltrate with admixed eosinophils around small
vessels in the upper dermis, but there were no spe-
cific findings from the middle dermis to the fatty tis-
sue (Fig. 1c). Laboratory tests, including complete
blood cell count and liver and kidney functions, were
within normal limits. Elevated hemoglobin A1c level
(8.4%; normal range, 4.6-6.2) was seen. The predni-
sone dose was decreased to 5 mgday and oral ad-
ministration of olopatadine hydrochloride (10 mg
day) and topical application of 0.05% difluprednate
were started. After 12 days, the prednisone was dis-
continued. The pruritic eruptions disappeared in 1
month after discontinuation of sitagliptin phosphate
hydrate. A positive lymphocyte transformation test
(LTT) reaction (stimulation index 2.0; normal <1.8)
with sitagliptin phosphate hydrate was obtained using
blood samples taken 7 days after discontinuation of
oral prednisolone. We diagnosed this case as
maculopapular-type drug eruption caused by sita-
gliptin phosphate hydrate.
In addition to this case, there have been 4 reports
of drug eruption caused by sitagliptin phosphate hy-
drate in the literature (Table 1).1-4 The patients (2
males and 3 females) were aged 59 to 66 years (mean
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Table　1　Cases of sitagliptin phosphate hydrate-induced drug eruption.
Ref. Case no Year Age Sex
Underlying
disease
Clinical
manifestations
Time 
inter-
val‡
Was
sitagliptin 
stopped?
Treatment RP LTT Patch test
Oral 
chal-
lenge 
test
Re-
currence
1 1 2012 62 F DM type 2,
HT
MPE 15 d Yes Topical steroid 1 w - - ND nw
2 2 2012 66 M DM type 2, 
Urticaria
Generalized 
skin eruption
6 m Yes Oral steroid, 
Topical steroid
1 m - nw nw nw
3 3 2012 65 M DM† Persistent 
edematous-
plaque photo-
sensitivity
2 w Yes Prevention of 
light transmit-
tance
2 y nw -§ nw nw
4 4 2012 59 F DM type 2, HT, 
Sarcoidosis
Psoriasiform 
eruption
6 d No Topical steroid 3 w nw nw nw -
Our 
case
5 2013 63 F DM type 2, 
Hyperlipemia
MPE 1 m Yes Oral steroid, 
Topical ste-
roid, Oral 
antihistamine
1 m + ND ND -
†Detailed information is not described in the case report. 
‡Time interval between start of sitagliptin phosphate hydrate and onset of symptoms. 
§Photopatch test. 
d, day; DM, diabetes mellitus; F, female; HT, hypertension; LTT, lymphocyte transformation test; M, male; m, month; MPE, maculopapular 
eruption; ND, not done; nw, not written; Ref, reference; RP, recovery period; w, week; y, year.
63.0, median 63.0 years) and 4 patients had used sita-
gliptin phosphate hydrate for treatment of type 2 dia-
betes mellitus. Types of eruptions included psoriasi-
form eruption, generalized skin eruption, persistent
edematous-plaque photosensitivity, and maculopapu-
lar eruption. Time interval between start of sitagliptin
phosphate hydrate and onset of symptoms ranged
from 6 days to 6 months, but it was 1 month in 4 of
the 5 patients, suggesting that the drug eruption may
commonly occur within a relatively short period of
time after intake of sitagliptin phosphate hydrate. In 4
of the 5 patients, the sitagliptin phosphate hydrate
was discontinued. The drug eruptions resolved
within 1 month, except for one patient with persistent
edematous-plaque photosensitivity. In one patient re-
ported by Mas-Vidal et al.,4 the psoriasiform eruption
caused by sitagliptin phosphate hydrate resolved in 3
weeks after starting topical steroid without stopping
the causative drug, suggesting that an eruption might
disappear despite continuance of a causative drug.
The eruptions were mainly treated with topical ster-
oids, oral steroids, and oral antihistamines. In one pa-
tient reported by Stricklin et al.,3 prevention of light
transmittance was effective for treatment of the erup-
tion. LTT with sitagliptin phosphate hydrate was posi-
tive in 1 of 3 evaluable cases, and negative patch test
results were reported in 2 evaluable cases. There was
no useful information from the oral challenge test. In
2 evaluable cases, no eruption recurrence was seen.
Desai et al. 5 summarized sitagliptin-associated
drug allergy from initial marketing of sitagliptin in
October 16, 2006, through November 24, 2008, in the
Adverse Event Reporting System database of the
Food and Drug Administration. Twenty six serious
skin reactions including 2 cases of Stevens-Johnson
syndrome and 2 cases of toxic epidermal necrolysis,
15 anaphylaxis, 4 angioedema, and 3 cutaneous vas-
culitis were confirmed.
In our case, the drug eruption caused by sitagliptin
phosphate hydrate was diagnosed based on a positive
LTT result. However, in other reports, the diagnosis
was based on the medical history, eruption, and clini-
cal course. This case is the first report of drug erup-
tion caused by sitagliptin phosphate hydrate with a
positive LTT. It is still unclear whether allergy tests,
including LTT and patch test, are useful or not be-
cause there have been only a limited number of re-
ported cases. In our case, the drug eruption may have
been caused by a type IV allergic reaction based on a
positive LTT result. DPP IV is expressed on B and
natural killer cells, and a specific set of T cells after
activation. It is also expressed on a restricted sub-
population of dendritic cells in lymph nodes draining
the skin and intestine.6 Therefore, DPP IV inhibitor
might modulate immune responses. Therefore, fur-
ther accumulation of data and careful observation of
the clinical course are required to improve the under-
standing of drug eruption caused by sitagliptin phos-
phate hydrate. This case also illustrates the impor-
tance of medical practitioners being aware of sita-
gliptin phosphate hydrate as a potential cause of drug
eruption.
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